The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | The potential role of CTCs as an independent prognostic factor in multiple myeloma
Pieter Sonneveld, MD, PhD, Erasmus MC, Rotterdam, Netherlands, discusses the potential of circulating tumor cells (CTCs) as a prognostic factor in multiple myeloma, highlighting that high CTC levels are an unfavorable prognostic factor and an independent predictor of outcome in multivariate analysis. Dr Sonneveld notes that CTC analysis using next-generation flow is a practical tool that can provide rapid results, making it a useful aid for clinicians to identify high-risk patients who may benefit from intensified therapy. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
